medigraphic.com
ISSN 1025-0298 (Electronic)
ISSN 1025-028X (Print)

2013, Number 2

Next >>

VacciMonitor 2013; 22 (2)

Epidemiological and microbiological features of 86 confirmed meningococcal disease cases in Cuba, 1998-2007

Rodríguez M, Pérez A, Llanes R, Dickinson F, Cuevas IE, Pérez K

Language: Spanish
References: 21
Page: 1-8
PDF size: 196.27 Kb.


ABSTRACT

The present study describes the behavior of meningococcal disease in 86 cases notified with isolation of Neisseria meningitidis in Cuba from 1998-2007, through spatial and temporal distribution of cases, phenotypic characterization of isolated strains and identification of some host risk factors that may affect phenotypic switching of strains. Percentages and the rate of changes of the strain phenotypic structure with different criteria were calculated. Children under one year old (30.2%) and meningitis (76.7%) were predominant. Case-fatality rate was 15.1%. The 58.1% of cases were ill with the same vaccine strain phenotype (B:4:P1.19,15). Phenotypic changes were detected in 41.9% of the isolates, mainly in children of 5-9 years old who live in western and central regions. Children that fell ill in July, September, December and April and live in Matanzas, Havana and Villa Clara provinces were associated to phenotypic switching of strains.


REFERENCES

  1. Climent Y, Yero D, Martínez I, Martin A, Jolley KA, Sotolongo F, et al. Clonal distribution of disease-associated and healthy carrier isolates of Neisseria meningitidis between 1983 and 2005 in Cuba. J Clin Microbiol 2010;48(3):802-10.

  2. Pereiro I, Diez-Domingo J, Segarra L, Ballester A, Albert A, Morant A. Risk factors for invasive disease among children in Spain. J Infect 2004;48(4):320-9.

  3. McCall BJ, Neill AS, Young MM. Risk factors for invasive meningococcal disease in southern Queensland, 2000-2001. Intern Med J 2004;34(8):464-8.

  4. Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis 1998;26:1159-64.

  5. Pérez A, de la Fuente L, Seuc A. Carga por enfermedad por meningitis bacteriana, Cuba 2006. Rev Cubana Med Trop 2012; 63(3):246-52.

  6. Racloz VN, Luiz SJ. The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology. BMC Infectious Diseases 2010;10:175.

  7. Raghunathan PL, Bernhardt SA, Rosenstein NE. Opportunities for control of meningococcal disease in the United States. Annu Rev Med 2004;55:333-53.

  8. Sharip A, Sorvillo F, Redelings MD, Mascola L, Wise M, Nguyen DM. Population-based analysis of meningococcal disease mortality in the United States: 1990-2002. Pediatr Infect Dis J 2006;25(3):191-4.

  9. Trotter CL, Chandra M, Cano R, Larrauri A, Ramsay ME, Brehony C, et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 2007;31(1):27-36.

  10. Martínez I. Contribución al transporte-conservación y caracterización de cepas aisladas en Cuba 1982-2002 [Tesis para optar al grado científico de Doctor en Ciencias Médicas]. La Habana: Instituto Finlay; 2004.

  11. Pérez AE, Dickinson FO, Rodríguez M. Community acquired bacterial meningitis in Cuba: a follow up of a decade. BMC Infectious Diseases 2010;10:130.

  12. Pace D, Cuschieri P, Galea A, Attard-Montalto S. Epidemiology of pathogenic Neisseria meningitidis serogroup B serosubtypes in Malta: Implications for introducing PorA based vaccines. Vaccine 2008;26:5952-6.

  13. Laboratorio Nacional de Referencia de Neisseria. Manual de Operaciones y Procedimientos del Laboratorio. La Habana: Instituto “Pedro Kourí”; 2007.

  14. Pérez A, Dickinson FO, Rodríguez M. Efectividad de la vacuna antimeningocócica VA-MENGOC-BC® en el primer año de vida, Cuba, 1997-2008. Rev Cubana Med Trop 2011;63(2):155-160.

  15. Sierra G, Campa C, Valcárcel M, García I, Izquierdo L, Sotolongo F. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991;14(2):195-207.

  16. Pirez GM, Picón MT, Galazka CT, Quian RJ, Gutiérrez RS, Ferrari CA, et al. Enfermedad invasiva meningocócica en Uruguay. Informe epidemiológico y recomendaciones, mayo 2002. Rev Med Uruguay 2002;18:83-8.

  17. González de Aledo, Viloria L. Serosubtipos de meningococo B causantes de enfermedad invasiva en Cantabria y concordancia con la cepa de la vacuna cubana. Gac Sanit 2004;18(1):45-9.

  18. Law DK, Lorange M, Ringuette L, Dion R, Giguere M, Henderson AM, et al. Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). J Clin Microbiol 2006;44(8):2743-9.

  19. Hernández CE, Pérez AE. Factores geológicos relacionados con problemas de salud. Rev Habanera Cien Med 2010; 9(2):219-29.

  20. Alcalá B, Arreaza L, Salcedo C, Uria MJ, de la Fuente L, Vázquez JA. Capsule switching among C:2b:P1.2,5 meningococcal epidemic strains after mass immunization campaign, Spain. Emerg Infect Dis 2002;8(12):1512-4.

  21. Climent Y, Urwin R, Yero D, Martínez I, Martin A, Sotolongo F, et al. The genetic structure of Neisseria meningitidis populations in Cuba before and after the introduction of a serogroup BC vaccine. Infect Genet Evol 2010;10(4):546-54.




2020     |     www.medigraphic.com